Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: October 25, 2010
Last updated: August 25, 2014
Last verified: August 2014
This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia A or B

Condition Intervention Phase
Congenital Bleeding Disorder
Haemophilia A
Haemophilia B
Drug: NNC 0172-0000-2021
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Number of adverse Events (AEs), including Serious Adverse Events (SAEs) [ Time Frame: from trial product administration until 43 days after trial product administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Area under the concentration-time curve [ Time Frame: from 43 days after trial product administration until 53 days after trial product administration ] [ Designated as safety issue: No ]
  • Adverse Events (AEs), including Serious Adverse Events (SAEs) [ Time Frame: from 43 days after trial product administration until 53 days after trial product administration ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: October 2010
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NNC 0172-0000-2021
Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
Experimental: B Drug: NNC 0172-0000-2021
Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
Placebo Comparator: C Drug: placebo
Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight between 50 and 100 kg, both inclusive
  • Body mass index (BMI) between 18.0 kg/m2 and 25.0 kg/m2, both inclusive
  • For haemophilia subjects only: Diagnosed with severe haemophilia A or B

Exclusion Criteria:

  • Known or suspected hypersensitivity to trial product(s) or related products
  • Surgery planned to occur during the trial
  • Any major and/or orthopaedic surgery within 30 days prior to trial product administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01228669

Wien, Austria, 1090
København, Denmark, 2100
Berlin, Germany, 10249
Kuala Lumpur, Malaysia, 50400
South Africa
Parktown Johannesburg, Gauteng, South Africa, 2193
Madrid, Spain, 28046
Zürich, Switzerland, 8091
Bangkok, Thailand, 10400
United Kingdom
Harrow, United Kingdom, HA1 3UJ
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT01228669     History of Changes
Other Study ID Numbers: NN7415-3813  2010-020465-24  U1111-1116-2356 
Study First Received: October 25, 2010
Last Updated: August 25, 2014
Health Authority: Austria: The Austrian Agency for Health and Food Safety (AGES)
Denmark: Danish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Malaysia: National Pharmaceutical Control Bureau
South Africa: Medicines Control Council
Spain: Spanish Agency of Medicines and Health Care Products
Switzerland: Swissmedic
Thailand: Ministry of Public Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Hemophilia A
Hemophilia B
Blood Coagulation Disorders
Hemostatic Disorders
Blood Coagulation Disorders, Inherited
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Vascular Diseases
Cardiovascular Diseases processed this record on December 07, 2016